Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets
This article was originally published in The Pink Sheet Daily
Executive Summary
The Lexington, Mass., biotech plans to start CXA-201 in HAP/VAP soon depending on how FDA guidance - due by the end of the year - plays out.